| Literature DB >> 29716811 |
Yoshiyuki Meguro1, Kanako Miyano2, Shigeto Hirayama3, Yuki Yoshida4, Naoto Ishibashi5, Takumi Ogino5, Yuriko Fujii2, Sei Manabe6, Moeko Eto4, Miki Nonaka2, Hideaki Fujii3, Yoichi Ueta7, Minoru Narita8, Naohiro Sata9, Toshihiko Yada10, Yasuhito Uezono11.
Abstract
Oxytocin (OT) is a 9-amine neuropeptide that plays an essential role in mammalian labor, lactation, maternal bonding, and social affiliation. OT has been reported to exert an analgesic effect in both humans and animals, and the results of certain animal experiments have shown that the analgesic effect of OT is partially blocked by opioid receptor antagonists. To investigate the relationship between OT and μ opioid receptor (MOR), we evaluated how OT affects MOR in vitro by performing an electrical impedance-based receptor biosensor assay (CellKey™ assay), an intracellular cAMP assay, and a competitive receptor-binding analysis by using cells stably expressing human MOR and OT receptor. In both the CellKey™ assay and the intracellular cAMP assay, OT alone exerted no direct agonistic effect on human MOR, but treatment with 10-6 M OT markedly enhanced the MOR signaling induced by 10-6 M endomorphin-1, β-endorphin, morphine, fentanyl, and DAMGO. Moreover, in the competitive receptor-binding assay, 10-6 M OT did not alter the affinity of endomorphin-1 or morphine for MOR. These results suggest that OT could function as a positive allosteric modulator that regulates the efficacy of MOR signaling, and thus OT might represent a previously unrecognized candidate analgesic agent.Entities:
Keywords: Analgesia; G protein-coupled receptor (GPCR); Oxytocin; Positive allosteric modulator; μ opioid receptor
Mesh:
Substances:
Year: 2018 PMID: 29716811 DOI: 10.1016/j.jphs.2018.04.002
Source DB: PubMed Journal: J Pharmacol Sci ISSN: 1347-8613 Impact factor: 3.337